A Call to Action for the Kidney Community

Bieber, Scott D.; Gadegbeku, Crystal A.

doi:10.2215/cjn.10470919

Cited by 11 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the United States, the recent executive order, Advancing American Kidney Health (AAKH), has stated three major goals: ( 1 ) a 25% decrease in kidney failure incidence by 2030, ( 2 ) an increase in the rate of home therapies to 80% for incident patients with kidney failure by 2025, and ( 3 ) a doubling of the rate of kidney transplantation by 2030 (18,19). In addition, AAKH creates funding/payment models such as the Kidney Care Choices and the Comprehensive Kidney Care Contracting, both of which provide strong financial incentives to US nephrologists, and managed care organizations/dialysis providers to lower Medicare Part A and B costs for recipients with CKD stage 4 (eGFR of 15–29 ml/min per 1.73 m 2 ) (20). To meet these targets, it is imperative to triage the higher-risk patients to receive multidisciplinary team–based care or patient management to optimize care to delay the rate of progression to kidney failure.…”

Section: Discussionmentioning

confidence: 99%

Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease

Prasad

Osman²,

Jafari

et al. 2022

CJASN

View full text Add to dashboard Cite

Background and objectivesPatients with CKD exhibit heterogeneity in their rates of progression to kidney failure. The kidney failure risk equation (KFRE) has been shown to accurately estimate progression to kidney failure in adults with CKD. Our objective was to determine health care utilization patterns of patients on the basis of their risk of progression.Design, setting, participants, & measurementsWe conducted a retrospective cohort study of adults with CKD and eGFR of 15–59 ml/min per 1.73 m2 enrolled in multidisciplinary CKD clinics in the province of Saskatchewan, Canada. Data were collected from January 1, 2004 to December 31, 2012 and followed for 5 years (December 31, 2017). We stratified patients by eGFR and risk of progression and compared the number and cost of hospital admissions, physician visits, and prescription drugs.ResultsIn total, 1003 adults were included in the study. Within the eGFR of 15–29 ml/min per 1.73 m2 group, the costs of hospital admissions, physician visits, and drug dispensations over the 5-year study period comparing high-risk patients with low-risk patients were (Canadian dollars) $89,265 versus $48,374 (P=0.008), $23,423 versus $11,231 (P<0.001), and $21,853 versus $16,757 (P=0.01), respectively. Within the eGFR of 30–59 ml/min per 1.73 m2 group, the costs of hospital admissions, physician visits, and prescription drugs were $55,944 versus $36,740 (P=0.10), $13,414 versus $10,370 (P=0.08), and $20,394 versus $14,902 (P=0.02) in high-risk patients in comparison with low-risk patients, respectively, for progression to kidney failure.ConclusionsIn patients with CKD and eGFR of 15–59 ml/min per 1.73 m2 followed in multidisciplinary clinics, the costs of hospital admissions, physician visits, and drugs were higher for patients at higher risk of progression to kidney failure by the KFRE compared with patients in the low-risk category. The high-risk group of patients with CKD and eGFR of 15–29 ml/min per 1.73 m2 had stronger association with hospitalizations costs, physician visits, and drug utilizations.

show abstract

Section: Discussionmentioning

confidence: 99%

Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease

Prasad

Osman²,

Jafari

et al. 2022

CJASN

View full text Add to dashboard Cite

show abstract

“…6 Underscoring the importance of CKD awareness, the National Kidney Foundation, American Society of Nephrology, and U.S. Department of Health and Human Services jointly announced a Public Awareness Initiative in 2019 as part of the Advancing American Kidney Health executive order. 7 To assess the impact of this initiative and to facilitate reliable national and local surveillance of CKD awareness, determining a baseline upon which to gauge improvement and an understanding of how different methods can affect estimates of CKD awareness is necessary. Prior studies of CKD awareness have used differently worded questions to describe kidney disease when ascertaining awareness including "chronic kidney disease", "weak or failing kidneys", and "kidney problem" among others.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Underscoring the importance of CKD awareness, the National Kidney Foundation, American Society of Nephrology, and US Department of Health and Human Services jointly announced a Public Awareness Initiative in 2019 as part of the Advancing American Kidney Health executive order. 7 …”

mentioning

confidence: 99%

Patient Awareness of CKD: A Systematic Review and Meta-analysis of Patient-Oriented Questions and Study Setting

et al. 2021

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…(c) the Advancing American Kidney Health Initiative 34 – 36 , which is an executive order that is prioritizing home dialysis.…”

Section: G) Creating An Innovation Substrate To Advance Patient-cente...mentioning

confidence: 99%

Advances in hemodialysis therapy

Thajudeen¹,

Issa²,

Roy‐Chaudhury³

2023

Fac Rev

View full text Add to dashboard Cite

End-stage renal disease (ESRD) continues to be a disease process with a high rate of hospitalization and mortality. There has been little innovation in nephrology over the last few decades compared to revolutionary high-tech advancements in other areas like oncology and cardiovascular medicine. Kidney transplantation, the only available alternative to renal replacement therapy, is limited in its availability. It is essential to have advances in this field to improve the efficiency of currently available treatments and devise new therapies. The current description of renal replacement therapy is inappropriate as it only replaces the filtration function of the failed kidney without addressing its other vital metabolic, endocrinologic, and immunologic roles and portability. Hence, it is critical to have newer therapies focusing on total replacement and portability, not just clearance. This review will address the developments in hemodialysis therapy. Advances in hemodialysis therapy include hemodiafiltration, portable machines, wearable artificial kidneys, and bioartificial kidneys. Although promising, newer technologies in this direction are still far from clinical application. Several organizations and enterprises including the Kidney Health Initiative and Kidney X: The Kidney Innovation Accelerator, as well as The Advancing American Kidney Health Initiative, are working in tandem to develop new therapies that could customize the treatment of ESRD.

show abstract

A Call to Action for the Kidney Community

Cited by 11 publications

References 2 publications

Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease

Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease

Patient Awareness of CKD: A Systematic Review and Meta-analysis of Patient-Oriented Questions and Study Setting

Advances in hemodialysis therapy

Contact Info

Product

Resources

About